Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
Casulo C, Dixon JG, Ou FS, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus R, Kimby E, Herold M, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Shi Q, Flowers CR. Casulo C, et al. Among authors: ladetto m. Blood Adv. 2021 Mar 23;5(6):1737-1745. doi: 10.1182/bloodadvances.2020002724. Blood Adv. 2021. PMID: 33749762 Free PMC article.
Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions.
Tarella C, Corradini P, Astolfi M, Bondesan P, Caracciolo D, Cherasco C, Ladetto M, Giaretta F, Ricca I, Vitolo U, Pileri A, Ferrero D. Tarella C, et al. Among authors: ladetto m. Leukemia. 1999 Sep;13(9):1456-62. doi: 10.1038/sj.leu.2401488. Leukemia. 1999. PMID: 10482999 Clinical Trial.
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiatelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambello R, Chisesi T, Di Renzo N, Vivaldi P, De Crescenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, Sorio M, Astolfi M, Drandi D, Pileri A, Tarella C. Ladetto M, et al. Blood. 2002 Sep 1;100(5):1559-65. doi: 10.1182/blood-2002-02-0621. Blood. 2002. PMID: 12176870 Free article. Clinical Trial.
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.
Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell'Aquila M, Alfarano A, Rossatto P, Rocci A, Vitolo U, Corradini P, Boccadoro M, Tarella C. Ladetto M, et al. Exp Hematol. 2003 Sep;31(9):784-8. doi: 10.1016/s0301-472x(03)00191-7. Exp Hematol. 2003. PMID: 12962724 Free article.
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.
Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. Ladetto M, et al. Leukemia. 2006 Oct;20(10):1840-7. doi: 10.1038/sj.leu.2404346. Epub 2006 Aug 24. Leukemia. 2006. PMID: 16932351 Clinical Trial.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Ladetto M, et al. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31. Blood. 2008. PMID: 18239086 Free article. Clinical Trial.
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma.
Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, Bruscaggin A, Franceschetti S, Fangazio M, De Paoli L, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Carbone A, Foà R, Gaidano G. Rossi D, et al. Among authors: ladetto m. Blood. 2011 Feb 24;117(8):2405-13. doi: 10.1182/blood-2010-07-296244. Epub 2010 Dec 14. Blood. 2011. PMID: 21156845 Free article.
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U. Pregno P, et al. Among authors: ladetto m. Blood. 2012 Mar 1;119(9):2066-73. doi: 10.1182/blood-2011-06-359943. Epub 2012 Jan 10. Blood. 2012. PMID: 22234681 Free article.
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. Ghielmini M, et al. Ann Oncol. 2013 Mar;24(3):561-76. doi: 10.1093/annonc/mds517. Epub 2012 Nov 21. Ann Oncol. 2013. PMID: 23175624 Free PMC article.
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Vitolo U, et al. Among authors: ladetto m. J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19. J Clin Oncol. 2013. PMID: 23960180 Clinical Trial.
227 results